Loading...
Loading...
- Teleflex Incorporated TFX reported Q2 FY22 revenues of $704.5 million, down 1.3% Y/Y, up 2.3% on a constant currency basis, missing the consensus of $719.50 million.
- Lower sales from the Interventional Urology segment impacted the revenue. The company did not see the expected operating environment recovery in the Interventional Urology business during the second quarter.
- Adjusted diluted EPS increased 1.2% to $3.39, exceeding the consensus of $3.34.
- The gross margin remained flat at 59%.
- FY22 Guidance: Teleflex cut GAAP and constant currency revenue growth guidance to (0.45)% to 0.55% and 3.25% to 4.25%, respectively.
- The company lowered adjusted EPS to $13.00 - $13.40 from $13.70 - $14.30, below the consensus of $13.97.
- Price Action: TFX shares are down 6.53% at $249.13 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in